Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a report issued on Sunday. The firm set a “sell” rating on the stock.

Separately, Roth Mkm reaffirmed a “buy” rating and issued a $20.00 target price on shares of Bio-Path in a research note on Monday, July 8th.

Bio-Path Stock Performance

BPTH opened at $0.93 on Friday. Bio-Path has a 12 month low of $0.86 and a 12 month high of $21.60. The business’s 50-day moving average price is $1.25 and its 200-day moving average price is $2.27.

Bio-Path (NASDAQ:BPTH) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($1.16) EPS for the quarter, topping analysts’ consensus estimates of ($1.54) by $0.38. During the same period in the previous year, the firm earned ($10.60) earnings per share. On average, equities analysts forecast that Bio-Path will post -6.2 earnings per share for the current fiscal year.

Institutional Trading of Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the second quarter, according to its most recent filing with the SEC. The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path as of its most recent filing with the SEC. Institutional investors own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.